Vir Biotechnology, Inc. (VIR) has a negative trailing P/E of -3.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -32.49%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -1.4 | 0.00 | -1.42 | 656.16 | - |
| 2018 | -11.7 | 0.13 | -7.58 | 1,565.34 | - |
| 2019 | -7.8 | -0.22 | 3.19 | 1,904.67 | - |
| 2020 | -10.7 | -0.19 | 4.45 | 47.45 | - |
| 2021 | 10.3 | -0.04 | 3.80 | 4.96 | - |
| 2022 | 6.5 | -1.47 | 1.62 | 2.08 | - |
| 2023 | -2.2 | 0.01 | 0.85 | 15.66 | - |
| 2024 | -1.9 | 0.12 | 0.87 | 13.48 | - |
| 2025 | -1.9 | 0.11 | 1.09 | 12.18 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.72 | $149K | $-69.85M | -46880.5% |
| 2018 | $-1.20 | $868K | $-115.88M | -13350.7% |
| 2019 | $-1.62 | $711K | $-174.68M | -24568.6% |
| 2020 | $-2.51 | $67.25M | $-298.67M | -444.1% |
| 2021 | $3.96 | $1.09B | $528.58M | 48.6% |
| 2022 | $3.83 | $1.58B | $515.84M | 32.6% |
| 2023 | $-4.59 | $86.18M | $-615.06M | -713.7% |
| 2024 | $-3.83 | $74.21M | $-521.96M | -703.4% |
| 2025 | $-3.16 | $68.56M | $-437.99M | -638.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.04 | $-3.63 – $-0.84 | $138.64M | $105.49M – $158.84M | 4 |
| 2027 | $-2.31 | $-2.91 – $-1.85 | $92.56M | $57.85M – $133.09M | 5 |
| 2028 | $-1.63 | $-1.91 – $-1.16 | $152.35M | $147.12M – $157.58M | 3 |
| 2029 | $-1.42 | $-1.90 – $-0.89 | $188.36M | $134.74M – $237.97M | 1 |
| 2030 | $-1.20 | $-1.60 – $-0.75 | $246.47M | $176.32M – $311.4M | 1 |
